IntoCell, Inc. (KOSDAQ:287840)
South Korea flag South Korea · Delayed Price · Currency is KRW
24,400
+900 (3.83%)
At close: Aug 4, 2025, 3:30 PM KST

IntoCell Company Description

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer.

It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers.

In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxin Library, an optimized linker-toxin library for fast delivery of a pre-clinical candidate in novel ADC programs.

The company was founded in 2015 and is based in Daejeon, South Korea.

IntoCell, Inc.
CountrySouth Korea
Founded2015
IndustryBiological Products, Except Diagnostic Substances
CEOTae-Kyo Park

Contact Details

Address:
101, Sinildong-ro
Daejeon
South Korea
Phone82 4 2716 0083
Websiteintocell.com

Stock Details

Ticker Symbol287840
ExchangeKOSDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyKRW
SIC Code2836

Key Executives

NamePosition
Tae-Kyo ParkChief Executive Officer
Young-Suk SuhChief Financial Officer